

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 74589

Title: Up to Seven Criteria in Selection of Systemic Therapy for Hepatocellular Carcinoma

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02936034

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Chief Doctor, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-12-29

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-12-29 03:56

Reviewer performed review: 2022-01-06 04:55

Review time: 8 Days

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

BCLC intermediate stage disease that exceeds “the up to seven” criteria, especially with lesions larger than 5cm, is less likely to respond to TACE alone and is therefore a disease that may respond better to systemic therapy. With the recent breakthroughs in immunotherapy for advanced HCC which clearly demonstrated OS advantage over single agent TKI sorafenib, it is promising that the use of immunotherapy would likely lead to better outcome when used in intermediate disease.